Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kanika, Dey"'
Autor:
Myron J. Levin, Andrew Ustianowski, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie Streicher, Alexandre Kiazand, Mark T. Esser
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 6, Pp 1253-1268 (2024)
Abstract Introduction The phase 3 PROVENT and STORM CHASER studies evaluated AZD7442 (tixagevimab/cilgavimab) for pre-exposure and post-exposure prophylaxis of symptomatic coronavirus disease 2019 (COVID-19). We report the final 15-month results of b
Externí odkaz:
https://doaj.org/article/a0dc96dc6a4541d2935ee2e82a120a9f
Autor:
Myron J, Levin, Andrew, Ustianowski, Steven, Thomas, Alison, Templeton, Yuan, Yuan, Seth, Seegobin, Catherine F, Houlihan, Ibrahim, Menendez-Perez, Simon, Pollett, Rosalinda H, Arends, Rohini, Beavon, Kanika, Dey, Pedro, Garbes, Elizabeth J, Kelly, Gavin C K W, Koh, Stefan, Ivanov, Karen A, Near, Audrey, Sharbaugh, Katie, Streicher, Menelas N, Pangalos, Mark T, Esser
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).Adults without prior SARS-CoV-2 infection or COVID-19 vaccination were enrolled
Autor:
Myron J, Levin, Andrew, Ustianowski, Stéphane, De Wit, Odile, Launay, Miles, Avila, Alison, Templeton, Yuan, Yuan, Seth, Seegobin, Adam, Ellery, Dennis J, Levinson, Philip, Ambery, Rosalinda H, Arends, Rohini, Beavon, Kanika, Dey, Pedro, Garbes, Elizabeth J, Kelly, Gavin C K W, Koh, Karen A, Near, Kelly W, Padilla, Konstantina, Psachoulia, Audrey, Sharbaugh, Katie, Streicher, Menelas N, Pangalos, Mark T, Esser, Michelle, Owens
Publikováno v:
The New England journal of medicine. 386(23)
The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophy